Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Beam Therapeutics reported Q2 2026 results with $0.5M revenue and a net loss of $(122.7) M, or $(1.18) diluted EPS. Revenue declined significantly from the prior year. Clinically, BEACON risto-cel dosing completed with promising data, targeting a BLA filing by year-end 2026. In vivo candidates are advancing, supported by a new cGMP facility and strategic collaborations providing non-dilutive funding.
Beam Therapeutics Inc. reported results for the second quarter of 2026 with revenue of $0.5M and a net loss attributable to Beam of $(122.7) M, producing a diluted loss per share of $(1.18) versus the year‑ago quarter.
Financial Highlights
- Revenue: $0.5M for 2Q 2026, down from $8.5M in 2Q 2025 (‑$8.0M YoY).
- Net income: Net loss attributable to Beam of $(122.7) M for 2Q 2026 versus net loss of $(102.1) M in 2Q 2025.
- Diluted EPS: $(1.18) loss per share for 2Q 2026 versus $(1.00) loss per share in 2Q 2025.
Business Highlights
- Clinical progress: BEACON risto‑cel Phase 1/2 completed dosing with durable high editing, hemoglobin F levels above 60% and reduced HbS; a BLA filing is targeted for year‑end 2026.
- LNP program momentum: In vivo liver‑targeted candidates BEAM‑302, ‑304 and ‑301 are advancing, with BEAM‑302 moving into a pivotal expansion cohort.
- Manufacturing and operations: A 100k sq ft cGMP facility is online to support both ex vivo and in vivo programs and potential commercial supply.
- Collaborations and licensing: Strategic alliances with Pfizer, Lilly/Verve, Apellis/Biogen and Orbital/BMS continue to provide program support and non‑dilutive milestone revenue.
- Funding and revenue mix: License and collaboration revenue growth was driven by a Lilly milestone; capital raises and an equity sales agreement support the company’s R&D runway.
Original SEC Filing: Beam Therapeutics Inc. [ BEAM ] - 10-Q - Aug. 04, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.